Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) currently has a daily average trading volume of 48.32K but it saw 17305485 shares traded in last market. With a market cap of 2.58M USD, the company’s current market price of $0.43 came rising about 42.43 while comparing to the previous closing price of $0.30. In past 52 weeks, the stock remained buoying in the range of price level as high as $0.90 and as low as $0.26. In the recent trading on the day, stock has struck highest price mark of $0.3001 while lowest mark touched by it was $0.441.
Taking a look at 20-day trading activity of Galmed Pharmaceuticals Ltd (GLMD) gives us an average price of $0.3033, while its current price level is -52.22% below from 52-week high level whereas it is 65.38% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.3075 while that of 200 days or SMA-200 reads an average of $0.3604. A closer look into the stock’s movement over the week reveals that its volatility is standing at 15.23% during that period while stretching the period over a month that decreases to 9.32%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 77.19 which implies that the stock is in overbought territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the B. Riley FBR which downgraded the stock as “Neutral” in its note to investors issued on May 22, 2020, recommending a price target of between $11 and $8 for it. Cantor Fitzgerald issued its recommendations for the stock as it resumed the price target for the stock in the range of between $9 and $14.
Over the week, GLMD’s stock price is moving 49.04% up while it is 36.46% when we observe its performance for the past one month. Year-to-date it is -5.49% down and over the past year, the stock is showing a downside performance of -51.06%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -1.09 beat the consensus estimate of -1.5 for the same. The company is expected to be releasing its next quarterly report on 2024-Apr-04, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Galmed Pharmaceuticals Ltd’s total number of outstanding shares is 6.01M with 3.66% of that held by the insiders while 6.57% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -49.84% and return on equity (ROE) at -51.38%. Stock’s beta reads 0.68. Stock has a price to book (P/B) ratio of 0.20. Its return on asset (ROA) is -43.37% on average.
